ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0739

One Year Outcomes in Those with Isolated PMR Recruited via a Fast Track PMR Clinic

Patricia Harkins1, Sharon Cowley2, Robert Harrington3, seoidin McKittrick4, David Kane5 and Richard Conway6, 1Trinity College Dublin, Dublin 8, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3St. James's Hospital, Dublin, Dublin, Ireland, 4University of Limerick, Limerick, Ireland, 5Tallaght University Hospital & Trinity College Dublin, D24, Ireland, 6Trinity College Dublin, Dublin, Ireland

Meeting: ACR Convergence 2024

Keywords: Outcome measures, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: To date the longitudinal outcomes of those with isolated Polymyalgia Rheumatica (PMR) are poorly understood, owing largely to the fact that in the majority of countries PMR is diagnosed and managed in primary care, with only a minority of cases referred for specialist evaluation.

The aim of our study, was therefore to establish for the first time the longitudinal outcomes of an Irish population with isolated PMR.  

Methods: Patients were recruited to this multicentre longitudinal cohort study from a newly established fast track PMR clinic, where those fulfilling the 2012 EULAR/ ACR Provisional PMR classification criteria were invited to participate. Those with symptoms or imaging confirmation of  cGCA/ LV-GCA were excluded. Those who had 12 month follow-up were included in the final analysis. The statistical analysis was performed using STATA MP Version 18. P values < 0.05 are considered statistically significant.

Results: A total of 65 patients, including 33 (50.8%)  females,  were recruited. Mean age at the time of diagnosis was 70.44 (SD 7.15). There was one death, and three subsequent cancer diagnoses and these were excluded from the final analysis.

At one year, 23/61 (27.7%) patients remained on glucocorticoid therapy, with a mean dose of 3.282 (SD 2.038). A total of 13/61 (21.3%) were commenced on steroid sparing therapy – tocilizumab.

There was a total of 33 disease relapses, in 20 /61 patients (32.7%). 12 patients experienced 2 or more relapses. The mean time to disease relapse was 6.55 (3.69) months, with a mean steroid dose at the time of relapse of 6.652 (SD 4.168). Increased duration of early morning stiffness (p=0.04), and higher PMR-AS (p=0.05) at disease presentation were significantly associated with disease relapse. 2 osteoporotic fractures, 1 Achilles tendon rupture, 11 Lower respiratory tract infections – 4 of which required hospital admission, 1 episode of shingles, 2 cases of diabetes mellitus, 1 transient Ischaemic attack, 2 non-ST elevation myocardial infarctions , 10 cases of mood disturbance, and 2 cases of sleep disturbance were reported.

Conclusion: This prospective study reports for the first time the longitudinal outcomes of an Irish PMR population, and emphasises both the disease and management burden. These findings also highlight the importance of specialist input in the care of those with isolated PMR. 


Disclosures: P. Harkins: Janssen Pharmaceuticals, 5, Novartis Pharmaceuticals, 5; S. Cowley: AbbVie/Abbott, 12, Support to attend conference, Novartis, 5, 12, Support to attend conference; R. Harrington: None; s. McKittrick: None; D. Kane: None; R. Conway: AbbVie/Abbott, 5, 6, Celltrion, 5, Fresenius Kabi, 6, Galapagos, 6, Janssen, 5, 6, Novartis, 5, 6, UCB, 6, Viatris, 6.

To cite this abstract in AMA style:

Harkins P, Cowley S, Harrington R, McKittrick s, Kane D, Conway R. One Year Outcomes in Those with Isolated PMR Recruited via a Fast Track PMR Clinic [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/one-year-outcomes-in-those-with-isolated-pmr-recruited-via-a-fast-track-pmr-clinic/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/one-year-outcomes-in-those-with-isolated-pmr-recruited-via-a-fast-track-pmr-clinic/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology